• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

One Ms really?

Quote

anonymous

Guest
This consolidated of S1P and Kesimpta teams is a disaster... how long until territories are collapsed and they say “well we only need 1 portfolio rep”. Dust off your resumes
 




Other MS companies have 2-3 that overlap territories. Biogen used to have 3 reps per territory until they had a downsizing but operated that way for 6-7yrs. Novartis just needs to not backfill position when people leave either side or get promoted. That’s my humble opinion, but I’m not a leader in charge.
 




Watch come December one of the reps will be cut. You both will have to interview for one job. So during a pandemic it's hard enough to see doctors. Now throw in another rep selling the same thing. What a stupid plan.
 








we have until Jan 2022-historically Novartis lays off the week after thanksgiving if this were to happen. Either way, you have a 9 month heads up notice to look for another opportunity.
 








anonymous said:
we have until Jan 2022-historically Novartis lays off the week after thanksgiving if this were to happen. Either way, you have a 9 month heads up notice to look for another opportunity.
Click to expand...

  • Spot on. Unless they see skyrocketing growth with Kesimpta. One of us will be gone by Thanksgiving. Just look at past history at Novartis. Don't give me Biogen as an example they had 3 one billion dollar products to sell.
 




anonymous said:
  • Spot on. Unless they see skyrocketing growth with Kesimpta. One of us will be gone by Thanksgiving. Just look at past history at Novartis. Don't give me Biogen as an example they had 3 one billion dollar products to sell
It’s possible we will see that type of growth since Mayzent launch wasn’t nearly as successful and now we are adding another body to call on targets. We may get to 2023 without a cut in the field if so.
Click to expand...
 








Ocrevus first 3 months sales = $200M+

Kesimpta first 3 months sales = $15M

Instead of the TLL Team perhaps Leverne, Vince and Dianne should be the ones polishing up their CVs???
 








TLL Team is a complete waste. Wtf do they do all day???? You guessed it. Nothing. Responsible for nothing, quotas for nothing, accountable for nothing. They will be the first to go.
 




























anonymous said:
Yeah Doug is a dick.
Click to expand...

unbossed? Ha. This company stinks. Every part about it. Wish I never came to this big pharma hell hole. I got what I deserved. TLL Team is useless. My boss is just as useless and we can’t sell a lick of this medication under all the “negatives” we have against us. A launch trajectory is made in the first 6 months and we have epically failed!
 




We need to be aligned with both east and west and that’s the not case with regards to initiatives and things being asked. I think most SS think ABL’s are useless, but they have a job to do as well so if you have someone who gets it then its fine which thankfully mine does. The issue arises when the RD overrides the ABL so the unbossed culture is nonexistent.
 




Top Bottom
Back
Quote